David Weingard, chief impact officer of T1D Moonshot and founder of Cecelia Health, tells us how T1D Moonshot aims to break silos and advance type 1 diabetes prevention and treatment option
In the first of a three-part series, Ben Hargreaves looks at what the odds are of another pandemic arising in our lifetimes and what can be done to lower the risk of this happening again.
pharmaphorum editor in chief Jonah Comstock talks to Philip Gomez, CEO of Siga Technologies, about how his company’s antiviral drug can play a crucial role in addressing monkeypox cases.
Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights activities within
